V
MRNA icon

Veritable’s Moderna MRNA Stock Holding History

Veritable’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,205
Closed -$632K – 514
2023
Q2 		$632K Sell
5,205
-644
-11% -$85.9K 0.01% 480
2023
Q1 		$898K Sell
5,849
-102
-2% -$16.8K 0.01% 395
2022
Q4 		$1.07M Sell
5,951
-1,159
-16% -$190K 0.02% 341
2022
Q3 		$841K Buy
7,110
+1,781
+33% +$270K 0.02% 385
2022
Q2 		$761K Buy
5,329
+494
+10% +$70.6K 0.01% 437
2022
Q1 		$833K Buy
4,835
+1,196
+33% +$201K 0.01% 435
2021
Q4 		$924K Sell
3,639
-977
-21% -$286K 0.01% 418
2021
Q3 		$1.78M Buy
4,616
+2,073
+82% +$765K 0.03% 264
2021
Q2 		$598K Buy
2,543
+624
+33% +$112K 0.01% 498
2021
Q1 		$251K Buy
+1,919
New +$278K ﹤0.01% 712

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Veritable's MRNA Position: Q3 2023 in Review

Veritable sold out of Moderna (MRNA) in Q3 2023, closing a stake of 5,205 shares — an estimated $632K sold.

Veritable first reported a position in MRNA in Q1 2021 and held it in 10 quarters. The position peaked at $1.78M in Q3 2021. 888 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Veritable reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Veritable sold 5,205 Moderna shares in Q3 2023, an estimated $632K.
  • Veritable first reported a position in Moderna in Q1 2021 and held it in 10 quarters.
  • Veritable's Moderna position peaked at $1.78M in Q3 2021.
  • 888 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.